1. either, a rise in serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activity to both ≥5 9 pre-rifampicin baseline and ≥5 9 upper limit of normal (ULN);
2. or, a rise in ALT or AST to both ≥3 9 pre-rifampicin baseline and ≥3 9 ULN with a concurrent rise in serum bilirubin to both ≥2 9 pre-rifampicin baseline and ≥2 9 ULN; 3. and, a Roussel-Uclaf Causality Assessment Method (RUCAM) score of ≥6 ("Probable" or "Highly probable") for rifampicin hepatitis. 18 Comparative statistics were used to compare groups that did, and that did not, develop hepatitis whilst taking rifampicin: the chi-squared test was used to compare categorical variables whilst the Mann-Whitney U-test was used to compare non-normally distributed numeric variables with normality assessed using the Shapiro-Wilk test; a P value of < 0.05 was considered significant.
Analyses were performed with StataMP v15.0 (StataCorp, College Station, TX, USA)
| RESULTS
We identified 116 out-patients prescribed rifampicin without concurrent isoniazid by the department of liver medicine between 2012 and 2016 inclusive ( Figure 1 ). Of these, four (2.4%) prescriptions were not made for the treatment pruritus and seven (6.0%) prescriptions were never commenced. 105 patients were therefore included in the final analysis.
One thousand three hundred and eighteen patients were prescribed rifampicin without isoniazid by departments other than liver medicine over the same time period. To assess whether these patients had received rifampicin for pruritus, 116 records were randomly selected. Table 2 ). The median time to diagnosis of rifampicin-induced hepatitis was 70 days (range 27-130).
There were no significant differences in baseline characteristics between patients who were diagnosed with rifampicin-induced hepatitis and those that were not (Table 1) . One further patient was diagnosed with rifampicin-associated acute kidney injury without associated hepatitis.
During our median follow-up of 809 days, we identified 29 patients who met biochemical criteria for potential DILI. Of these, 21 had undergone liver transplantation immediately prior to the derangement in liver biochemistry and were not further analysed. Of the remaining 8, 5 represented rifampicin-related DILI as assessed by RUCAM and are described in Table 2 . Three patients' derangements in liver biochemistry were scored as not related to rifampicin. continued to take rifampicin at the point of data collection. Figure 3 details the proportion of patients who remained free of major adverse events, minor adverse events and who continued to take rifampicin over the time period studied. 
| DISCUSSION
Here, we present the largest, real-world, cohort of patients treated with rifampicin for pruritus in liver disease published to date. Within our mixed aetiology cohort, we demonstrate that 95% of patients did not have any concern for hepatotoxicity, but that in 5% a rifampicininduced hepatitis was diagnosed. This finding is in contrast with the literature from controlled trials of rifampicin for pruritus where no cases of hepatitis were reported, but is consistent with isolated case reports and the literature derived from tuberculosis therapy. Our hepatitis rate of 4.8% is higher than the median of 1.1% reported for tuberculosis treatment regimens not containing isoniazid by one meta-analysis, but is within the range of rates reported for tuberculosis patients treated with both isoniazid and rifampicin, 11 and less than reported rates of 10%-20% for any increase in serum transaminase activity reported with rifampicin therapy. 19 Attributing liver injury to a given potential causative agent is challenging. In this study we used the established RUCAM, which has been widely used in other studies and has the benefit of being points-based rather than explicitly relying on individual opinion.
However, it is important to note that recent commentary and guidelines have also emphasised the value of expert opinion in diagnosing DILI. 20, 21 Furthermore, the RUCAM has been suggested to potentially underestimate the rate of drug-induced liver injury and to demonstrate more inter-assessor variability than other methodology. 22 In this study, we used a variation on the original RUCAM to account for deranged baseline liver biochemistry. Although such an adjustment is consistent with that promoted by a body expert opinion, it represents a variation from the initial RUCAM specification and is therefore likely to have differing sensitivity and sensitivity for diagnosing DILI. 17 Although the number of patients who developed rifampicininduced hepatitis in our cohort is small and our analysis is retrospective, there were no statistically significant distinguishing features that predicted subsequent development of hepatitis; a much larger cohort would, however, be necessary to investigate risk factors more conclusively. This is in contrast with the work on those treated for mycobacterial infection with rifampicin, where alcohol excess, low BMI, low serum albumin, age and gender have been suggested as predisposing factors. 10, 11, 23, 24 Multi-centre studies will be needed to further investigate potential risk factors for rifampicin-induced hepatitis in the context of liver disease. Table 2 Our cohort included some 23 patients with a baseline serum bilirubin of over 100 lmol/L ( ≥ 5.8 mg/dL). The UK package insert of rifampicin states that its use is contra-indicated in jaundice, although anecdotally many liver clinicians will consider using rifampicin for the treatment of pruritus despite jaundice. 25 We note, however, that it is our practice to co-prescribe oral vitamin K for icteric patients receiving rifampicin to reduce the risk of coagulopathy. 26 None of our markedly jaundiced patients developed hepatitis and we note that a separately reported group of markedly jaundiced patients with hepatocellular secretory failure predominantly attributed to biliary transporters dysfunction are reported as having safely received rifampicin for up to 10 weeks. 27 Of our cohort, although one patient required corticosteroids and admission to hospital, none of our 105 patients developed life-threatening complications from rifampicin despite some having advanced liver disease at baseline. Given that there was no established protocol for the monitoring of liver biochemistry during the time period assessed, it is possible that some further sub-clinical rifampicin-induced hepatitis may have escaped diagnosis. Nevertheless, our results suggest that rifampicin therapy is relatively safe in cholestatic jaundice.
Liver patients with cholestatic disorders may be prescribed multiple therapeutic compounds and our cohort was taking a median of 5 nonrifampicin medications. Although this number did not vary between groups that did and did not develop rifampicin-associated hepatitis, we cannot exclude the potential for drug-drug interactions promoting hepatitis, especially considering that over 20% of our patients were taking long-term antibiotics, predominantly as prophylaxis against recurrent cholangitis. A further variable that cannot be T A B L E 2 Liver biochemistry at baseline and at diagnosis of rifampicin induced hepatitis 
